StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Several other research firms have also weighed in on CTSO. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $1.05 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.04. The firm has a market capitalization of $57.41 million, a P/E ratio of -2.92 and a beta of 0.61. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. During the same period in the previous year, the firm posted ($0.21) EPS. On average, research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents in the 3rd quarter worth $51,000. Raymond James Financial Inc. purchased a new position in Cytosorbents during the fourth quarter worth about $99,000. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Finally, Skylands Capital LLC boosted its holdings in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.